Pasithea Therapeutics Corp.
KTTA
$0.73
-$0.03-4.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.73% | -14.92% | -2.65% | -34.25% | -11.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.89% | -8.94% | -36.69% | -20.71% | 3.04% |
| Operating Income | 3.89% | 8.94% | 36.69% | 20.71% | -3.04% |
| Income Before Tax | 3.88% | 7.71% | 36.84% | 16.96% | -7.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.88% | 7.71% | 36.84% | 16.96% | -7.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.88% | 7.71% | 37.05% | 16.96% | -2.74% |
| EBIT | 3.89% | 8.94% | 36.69% | 20.71% | -3.04% |
| EBITDA | 4.05% | 9.30% | 37.89% | 21.64% | -3.17% |
| EPS Basic | 82.22% | 56.49% | 44.30% | -0.05% | -28.64% |
| Normalized Basic EPS | 82.22% | 56.50% | 43.91% | -0.05% | -34.55% |
| EPS Diluted | 82.22% | 56.49% | 44.30% | -0.05% | -28.64% |
| Normalized Diluted EPS | 82.22% | 56.50% | 43.91% | -0.05% | -34.55% |
| Average Basic Shares Outstanding | 440.72% | 112.11% | 2.27% | -17.01% | -20.14% |
| Average Diluted Shares Outstanding | 440.72% | 112.11% | 2.27% | -17.01% | -20.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |